After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and Alzheimer's treatments.
Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...
Sage Therapeutics has launched another round of layoffs as it deals with the fallout of abandoning a key pipeline drug ...
Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...
Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple ...
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
13h
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...
Sage on Thursday said the moves will affect more than 165 employees, representing about 33% of the Cambridge, Mass., company's total workforce and roughly 55% of its research-and-development staff.
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback